Nucleus Network is Australia’s premier Phase 1 clinical trials organization and is also the world’s only multi-site, multi-country Phase 1 clinical trial specialist, operating in Australia and the USA.
Specializing in first-in-human clinical trials, we conduct Phase 1 trials for international Pharmaceutical and Biotechnology companies and have extensive experience with both biologic and small molecule products across most therapeutic areas.
Established in 2004, and operating Australia’s two largest facilities with a combined 150+ beds, our state-of-the-art Melbourne and Brisbane clinics are both co-located in cutting-edge medical research precincts, within two of Australia’s leading hospitals.
Our Melbourne facility has extensive pharmacodynamic biomarker capabilities, including on-site access to imaging facilities, respiratory facilities, gastroenterology facilities and anaesthetic services. Pharmacodynamic capabilities also extend to immunology services (including flow cytometry and immune activation) and bioanalytical services through onsite external vendors.
Specializing in vaccine and biosimilar studies, our Brisbane facility has purpose-built infrastructure to support the high-volume participant and outpatient requirements of these clinical trial designs. This facility is also supported by external bioanalytical and pharmacodynamic laboratories.
Located in Medical Alley Minneapolis, our US facility offers another 50 beds and has the versatility to conduct Healthy Volunteer studies as well as specialization in Renal, Hepatic and GI studies.
With access to a combined population of over 10.5 million people across our three sites, our dedicated and well-resourced recruitment team are known for their ability to successfully recruit both healthy volunteers and patients to a broad range of clinical trial designs.
Conducting an average of 100 trials annually, approximately 50% of which are FIH, Nucleus Network specializes in SAD/MAD, DDI, biosimilar, vaccine and ethnopharmacology across most therapeutic areas.
Australia is becoming the clinical trial destination of choice for several compelling reasons.
1. Speed – you can have first-patient-in in around 7-8 weeks and do not need an IND to commence
2. Quality – data generated is accepted by FDA and EMA
3. Cost – the Australian R&D tax incentive offers up to 43.5% cash rebate for work performed there
Together with our clients, we are fulfilling our purpose of “Advancing medicine, improving lives.”
Please contact Jeffrey Wong – Director of Business Development – email@example.com.